Related Experiment Video
Updated: Nov 5, 2025
Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer
Published on: May 18, 2020
Preclinical Advances in Theranostics for the Different Molecular Subtypes of Breast Cancer
Hanyi Fang1,2,3, Alessandra Cavaliere1, Ziqi Li1,4
1PET Center, Department of Radiology and Biomedical Imaging, School of Medicine, Yale University, New Haven, CT, United States.
Abstract:
Breast cancer is the most common cancer in women worldwide. The heterogeneity of breast cancer and drug resistance to therapies make the diagnosis and treatment difficult. Molecular imaging methods with positron emission tomography (PET) and single-photon emission tomography (SPECT) provide useful tools to diagnose, predict, and monitor the response of therapy, contributing to precision medicine for breast cancer patients. Recently, many efforts have been made to find new targets for breast cancer therapy to overcome resistance to standard of care treatments, giving rise to new therapeutic agents to offer more options for patients with breast cancer. The combination of diagnostic and therapeutic strategies forms the foundation of theranostics. Some of these theranostic agents exhibit high potential to be translated to clinic. In this review, we highlight the most recent advances in theranostics of the different molecular subtypes of breast cancer in preclinical studies.
Insights
This review explores recent advances in breast cancer theranostics for different molecular subtypes. These combined diagnostic and therapeutic approaches show promise for overcoming drug resistance and improving precision medicine in preclinical studies.
Area of Science:
- Oncology
- Radiochemistry
- Molecular Imaging
Background:
- Breast cancer is a leading global cancer in women, characterized by heterogeneity and therapeutic resistance.
- Current diagnostic and treatment strategies face challenges due to tumor complexity and drug resistance.
- Molecular imaging techniques like PET and SPECT are crucial for precision medicine in breast cancer management.
Purpose of the Study:
- To review recent preclinical advancements in breast cancer theranostics.
- To highlight novel therapeutic targets and agents for overcoming treatment resistance.
- To discuss the potential clinical translation of emerging theranostic strategies.
Main Methods:
- Literature review of recent preclinical studies on breast cancer theranostics.
- Focus on molecular imaging (PET/SPECT) and targeted therapies.
- Analysis of theranostic approaches across different breast cancer molecular subtypes.
Main Results:
- Significant progress in developing novel theranostic agents for various breast cancer subtypes.
- Demonstration of theranostics' potential in overcoming drug resistance in preclinical models.
- Identification of promising agents with high potential for clinical translation.
Conclusions:
- Theranostics offer a powerful strategy for personalized breast cancer treatment.
- Recent preclinical advances show great promise for improving patient outcomes.
- Further research and clinical translation are essential to realize the full potential of breast cancer theranostics.
